JP2016501516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501516A5 JP2016501516A5 JP2015540802A JP2015540802A JP2016501516A5 JP 2016501516 A5 JP2016501516 A5 JP 2016501516A5 JP 2015540802 A JP2015540802 A JP 2015540802A JP 2015540802 A JP2015540802 A JP 2015540802A JP 2016501516 A5 JP2016501516 A5 JP 2016501516A5
- Authority
- JP
- Japan
- Prior art keywords
- test compound
- hslc
- fragment
- loss
- cultured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 238000000034 method Methods 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 15
- 230000007547 defect Effects 0.000 claims 9
- 206010043275 Teratogenicity Diseases 0.000 claims 7
- 231100000211 teratogenicity Toxicity 0.000 claims 7
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 6
- 229960003067 cystine Drugs 0.000 claims 6
- 229960003104 ornithine Drugs 0.000 claims 6
- 231100000378 teratogenic Toxicity 0.000 claims 4
- 230000003390 teratogenic effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 claims 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 claims 1
- 238000007398 colorimetric assay Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims 1
- 210000002242 embryoid body Anatomy 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000010324 immunological assay Methods 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 238000013207 serial dilution Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721746P | 2012-11-02 | 2012-11-02 | |
| US61/721,746 | 2012-11-02 | ||
| US201361827407P | 2013-05-24 | 2013-05-24 | |
| US61/827,407 | 2013-05-24 | ||
| PCT/US2013/067980 WO2014071137A1 (en) | 2012-11-02 | 2013-11-01 | Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018091559A Division JP6581244B2 (ja) | 2012-11-02 | 2018-05-10 | ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501516A JP2016501516A (ja) | 2016-01-21 |
| JP2016501516A5 true JP2016501516A5 (cg-RX-API-DMAC7.html) | 2016-11-04 |
| JP6339581B2 JP6339581B2 (ja) | 2018-06-06 |
Family
ID=50628081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540802A Active JP6339581B2 (ja) | 2012-11-02 | 2013-11-01 | ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 |
| JP2018091559A Active JP6581244B2 (ja) | 2012-11-02 | 2018-05-10 | ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018091559A Active JP6581244B2 (ja) | 2012-11-02 | 2018-05-10 | ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20150301025A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2914748B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6339581B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104822843B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2888064C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2914748T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE043604T2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX362991B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014071137A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3019624B1 (en) * | 2013-07-09 | 2020-09-16 | Stemina Biomarker Discovery, Inc. | Biomarkers of autism spectrum disorder |
| FI126398B (en) | 2014-12-18 | 2016-11-15 | Upm Kymmene Corp | Method for chemical testing |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| CN109207551B (zh) * | 2017-07-07 | 2023-05-26 | 上海睿智化学研究有限公司 | 一种筛选叶酸代谢相关药物的方法 |
| US20210072230A1 (en) * | 2018-03-09 | 2021-03-11 | Stemina Biomarker Discovery, Inc. | In vitro assay to predict cardiotoxicity |
| WO2022112568A1 (en) * | 2020-11-30 | 2022-06-02 | Sanofi | Classifying images of dose-response graphs |
| CN119667130B (zh) * | 2025-02-13 | 2025-05-09 | 生态环境部华南环境科学研究所(生态环境部生态环境应急研究所) | 一种基于血清组氨酸/犬尿氨酸快速评估双酚类物质暴露毒性效应的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| WO2006124748A2 (en) * | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Multicyclic compounds and methods of their use |
| BRPI0710054B8 (pt) * | 2006-04-10 | 2021-07-27 | Wisconsin Alumni Res Found | métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste |
| AU2011232577C1 (en) * | 2010-03-22 | 2016-07-14 | Stemina Biomarker Discovery, Inc. | Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics |
| CA2798132A1 (en) * | 2010-05-14 | 2011-11-17 | Deseret Biologicals, Inc. | Formulations of diluted genetic material and methods for making same |
| US9447506B2 (en) | 2012-07-30 | 2016-09-20 | David Whitmore | Cathodic protection of a concrete structure |
-
2013
- 2013-11-01 JP JP2015540802A patent/JP6339581B2/ja active Active
- 2013-11-01 CA CA2888064A patent/CA2888064C/en active Active
- 2013-11-01 HU HUE13850210A patent/HUE043604T2/hu unknown
- 2013-11-01 US US14/439,723 patent/US20150301025A1/en not_active Abandoned
- 2013-11-01 DK DK13850210.9T patent/DK2914748T3/da active
- 2013-11-01 WO PCT/US2013/067980 patent/WO2014071137A1/en not_active Ceased
- 2013-11-01 MX MX2015005476A patent/MX362991B/es unknown
- 2013-11-01 EP EP13850210.9A patent/EP2914748B1/en active Active
- 2013-11-01 CN CN201380057328.0A patent/CN104822843B/zh active Active
-
2017
- 2017-12-20 US US15/848,188 patent/US10209240B2/en active Active
-
2018
- 2018-05-10 JP JP2018091559A patent/JP6581244B2/ja active Active
- 2018-12-18 US US16/224,150 patent/US20190128872A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501516A5 (cg-RX-API-DMAC7.html) | ||
| CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| EP4249605A3 (en) | Methods for analyte detection | |
| MX2009013411A (es) | Deteccion de antigenos transportados por eritrocitos y de anticuerpos anti-eritrocitos. | |
| ECSP088081A (es) | Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente | |
| WO2013086429A3 (en) | Methods and compositions for classification of samples | |
| WO2011149942A3 (en) | Compositions and methods for plasma peptide analysis | |
| MX2018002483A (es) | Equipos y métodos novedosos para detectar trastornos de ciclo de urea que usan espectrometría de masas. | |
| WO2012097081A3 (en) | Protein detection method | |
| WO2014143343A8 (en) | Hcv core lipid binding domain monoclonal antibodies | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| WO2010002911A3 (en) | Methods and materials for monitoring myeloma using quantitative mass spetrometry | |
| BR112013023540A2 (pt) | anticorpo, kit e método para a determinação de peptídeos amilóides | |
| BR112014004543A2 (pt) | método de síntese de proteínas | |
| WO2014074835A3 (en) | Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone | |
| WO2014066271A8 (en) | Non-b-lineage cells capable of producing antibody | |
| WO2012170206A3 (en) | Color-producing diagnostic systems, reagents and methods | |
| WO2013026026A3 (en) | Shift correction for spectral analysis | |
| ZA202105176B (en) | Method of characterization of visible and/or sub-visible particles in biologics | |
| CY1120220T1 (el) | Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση | |
| WO2012164525A3 (en) | Aging biomarkers | |
| WO2015184321A3 (en) | Rare molecule detection | |
| RU2015104737A (ru) | Способ обнаружения мультиспецифического связывающего агента | |
| WO2010056889A3 (en) | Use of an antibody and a rare-earth based crystal | |
| WO2012103337A3 (en) | Assays and methods to sequence microbes directly from immune complexes |